Concept’s Abluminus NP Polymer-Free DES and Antiplatelet Strategies Studied in STARS-DAPT

January 23, 2026—Concept Medical Inc., announced the enrollment of the first patients in the STARS DAPT randomized controlled trial (RCT) of ST-segment elevation myocardial infarction (STEMI) treated with the company’s Abluminus np—a polymer-free, sirolimus-based, nanocarrier eluting stent—and a P2Y12 inhibitor-based single antiplatelet strategy after a short dual antiplatelet therapy (DAPT) versus conventional DAPT.

The trial will assess the different strategies to manage acute coronary syndrome patients with an antiplatelet regimen.

Concept Medical advised that the Principal Investigator is Juan F. Iglesias, MD, of Geneva University Hospitals and University of Geneva in Geneva, Switzerland. The first four patients were enrolled by Professor Barbara Stähli, MD, at the University Hospital of Zurich in Zurich, Switzerland.

According to the company, the STARS DAPT RCT is an investigator-initiated, prospective, multicenter, international, open-label pilot study. The trial will enroll 350 all-comer patients with STEMI undergoing primary percutaneous coronary intervention with the Abluminus np device.

The study aims to evaluate the difference between a P2Y12 receptor inhibitor-based single antiplatelet therapy regimen after a short period of DAPT versus the conventional 6- or 12-month regimen of DAPT. The coprimary endpoints at 12 months are major adverse cardiac and cerebrovascular events and major bleeding complications, stated Concept Medical.